Skin2Neuron
Sydney, Australia· Est.
Autologous hair‑follicle‑derived neuron therapy targeting Alzheimer’s disease and broader neurodegeneration.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $4.4M
AI Company Overview
Autologous hair‑follicle‑derived neuron therapy targeting Alzheimer’s disease and broader neurodegeneration.
Alzheimer's diseaseParkinson's diseaseEpilepsyHuntington's disease
Technology Platform
Proprietary isolation and expansion of hair‑follicle‑derived neuroprecursor (HFN) cells, which are unipotent, gene‑modification‑free neurons suitable for autologous transplantation and in‑vitro neuronal culture.
Opportunities
Expansion of the autologous neuron platform into multiple neurodegenerative indications and commercialization of bespoke neuronal cultures for pharma‑driven drug discovery.
Risk Factors
Clinical translation uncertainty, manufacturing scalability, and stringent regulatory pathways for autologous cell therapies could delay market entry.
Competitive Landscape
Few competitors offer autologous, gene‑free neuronal therapies; S2N differentiates through hair‑follicle‑derived unipotent neurons and a repeatable manufacturing process.